Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). / Marzec, Michal; Zhang, Qian; Goradia, Ami; Raghunath, Puthiyaveettil N; Liu, Xiaobin; Paessler, Michele; Wang, Hong Yi; Wysocka, Maria; Cheng, Mangeng; Ruggeri, Bruce A; Wasik, Mariusz A.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 105, No. 52, 30.12.2008, p. 20852-7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Marzec, M, Zhang, Q, Goradia, A, Raghunath, PN, Liu, X, Paessler, M, Wang, HY, Wysocka, M, Cheng, M, Ruggeri, BA & Wasik, MA 2008, 'Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)', Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 52, pp. 20852-7. https://doi.org/10.1073/pnas.0810958105

APA

Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., & Wasik, M. A. (2008). Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America, 105(52), 20852-7. https://doi.org/10.1073/pnas.0810958105

Vancouver

Marzec M, Zhang Q, Goradia A, Raghunath PN, Liu X, Paessler M et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proceedings of the National Academy of Sciences of the United States of America. 2008 Dec 30;105(52):20852-7. https://doi.org/10.1073/pnas.0810958105

Author

Marzec, Michal ; Zhang, Qian ; Goradia, Ami ; Raghunath, Puthiyaveettil N ; Liu, Xiaobin ; Paessler, Michele ; Wang, Hong Yi ; Wysocka, Maria ; Cheng, Mangeng ; Ruggeri, Bruce A ; Wasik, Mariusz A. / Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). In: Proceedings of the National Academy of Sciences of the United States of America. 2008 ; Vol. 105, No. 52. pp. 20852-7.

Bibtex

@article{74019a9504a54e5fa5a4fd521323b88b,
title = "Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)",
abstract = "The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation. Here we report that the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as determined on the mRNA and protein level. The CD274 expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK+TCL cells by the small molecule ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone. NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3. STAT3 binds to the CD274 gene promoter in vitro and in vivo, as shown in the gel electromobility shift and chromatin immunoprecipitation assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion. These findings identify an additional cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein. These results also provide an additional rationale to therapeutically target NPM/ALK and STAT3 in ALK+TCL. Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clinical efficacy.",
keywords = "Antigens, CD, Antigens, CD274, Cell Line, Tumor, Cell Proliferation, Cell Survival, Enzyme Inhibitors, Gene Expression Regulation, Leukemic, Humans, Lymphoma, T-Cell, Oncogene Proteins, Fusion, Protein-Tyrosine Kinases, RNA, Small Interfering, STAT3 Transcription Factor, Journal Article, Research Support, N.I.H., Extramural",
author = "Michal Marzec and Qian Zhang and Ami Goradia and Raghunath, {Puthiyaveettil N} and Xiaobin Liu and Michele Paessler and Wang, {Hong Yi} and Maria Wysocka and Mangeng Cheng and Ruggeri, {Bruce A} and Wasik, {Mariusz A}",
year = "2008",
month = dec,
day = "30",
doi = "10.1073/pnas.0810958105",
language = "English",
volume = "105",
pages = "20852--7",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "The National Academy of Sciences of the United States of America",
number = "52",

}

RIS

TY - JOUR

T1 - Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

AU - Marzec, Michal

AU - Zhang, Qian

AU - Goradia, Ami

AU - Raghunath, Puthiyaveettil N

AU - Liu, Xiaobin

AU - Paessler, Michele

AU - Wang, Hong Yi

AU - Wysocka, Maria

AU - Cheng, Mangeng

AU - Ruggeri, Bruce A

AU - Wasik, Mariusz A

PY - 2008/12/30

Y1 - 2008/12/30

N2 - The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation. Here we report that the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as determined on the mRNA and protein level. The CD274 expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK+TCL cells by the small molecule ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone. NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3. STAT3 binds to the CD274 gene promoter in vitro and in vivo, as shown in the gel electromobility shift and chromatin immunoprecipitation assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion. These findings identify an additional cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein. These results also provide an additional rationale to therapeutically target NPM/ALK and STAT3 in ALK+TCL. Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clinical efficacy.

AB - The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation. Here we report that the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as determined on the mRNA and protein level. The CD274 expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK+TCL cells by the small molecule ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone. NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3. STAT3 binds to the CD274 gene promoter in vitro and in vivo, as shown in the gel electromobility shift and chromatin immunoprecipitation assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion. These findings identify an additional cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein. These results also provide an additional rationale to therapeutically target NPM/ALK and STAT3 in ALK+TCL. Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clinical efficacy.

KW - Antigens, CD

KW - Antigens, CD274

KW - Cell Line, Tumor

KW - Cell Proliferation

KW - Cell Survival

KW - Enzyme Inhibitors

KW - Gene Expression Regulation, Leukemic

KW - Humans

KW - Lymphoma, T-Cell

KW - Oncogene Proteins, Fusion

KW - Protein-Tyrosine Kinases

KW - RNA, Small Interfering

KW - STAT3 Transcription Factor

KW - Journal Article

KW - Research Support, N.I.H., Extramural

U2 - 10.1073/pnas.0810958105

DO - 10.1073/pnas.0810958105

M3 - Journal article

C2 - 19088198

VL - 105

SP - 20852

EP - 20857

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 52

ER -

ID: 179557614